Impact of HPV vaccination on anogenital warts and respiratory papillomatosis

References

• Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30(Suppl 5):F12-23; PMID:23199955; http://dx.doi.org/10.1016/j.vaccine.2012.07.055
   PubMed Web of Science ®Google Scholar
• Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27; PMID:12571259; http://dx.doi.org/10.1056/NEJMoa021641
   PubMed Web of Science ®Google Scholar
• Markowitz L, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, Bocchini JA, Jr, Unger ER. Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices. MMWR 2014; 63(No.RR-5):1-30; PMID:25167164
   PubMed Web of Science ®Google Scholar
• Petrosky E, Bocchini JA, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE. Use of 9-valent human papillomavirus (HPV) vaccine: updated vaccination recommendations of the advisory committee on immunization practices. MMWR 2015; 64(11):300-4; PMID:25811679
   PubMed Web of Science ®Google Scholar
• Lacey CJN, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24(Suppl 3):S3/35-41; PMID:16950016
   PubMedGoogle Scholar
• Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013; 13:39; PMID:23347441; http://dx.doi.org/10.1186/1471-2334-13-39
   PubMed Web of Science ®Google Scholar
• Park IU, Introcaso C, Dunne EF. Human papillomavirus and genital warts: a review of the evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis 2015; 61(Suppl 8):S849-55; PMID:26602622; http://dx.doi.org/10.1093/cid/civ813
   PubMed Web of Science ®Google Scholar
• Workowski KA, Bolan GA. Sexually Transmitted Diseases Treatment Guidelines 2015: Anogenital Warts. MMWR Recomm Rep 2015; 64(3):86-7
   Web of Science ®Google Scholar
• Gillison ML, Alemany L, Snijders PJF, Chaturvedi A, Steinberg BM, Schwartz S, Castellsagué X. Human papillomavirus and diseases of the upper airway: head and neck cancers and respiratory papillomatosis. Vaccine 2012; 30(Suppl 5):F34-54; PMID:23199965; http://dx.doi.org/10.1016/j.vaccine.2012.05.070
   PubMedGoogle Scholar
• Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003; 101:645-52; PMID:12681865
   PubMed Web of Science ®Google Scholar
• Venkatesan NN, Pine HS, Underbrink MP. Recurrent respiratory papillomatosis. Otolaryngol Clin North Am 2012; 45(3):671-94; PMID:22588043; http://dx.doi.org/10.1016/j.otc.2012.03.006
   PubMed Web of Science ®Google Scholar
• Burchell AN, Winer RL, de Sanjose S, Franco EL. Epidemology and transmission dynamics of HPV infection. Vaccine 2006; 24(3):52-6; http://dx.doi.org/10.1016/j.vaccine.2006.05.031
   Web of Science ®Google Scholar
• Oriel JS. Natural history of genital warts. Br J Vener Dis 1971; 47:1-13; PMID:5550858
   PubMedGoogle Scholar
• Forcier M, Musacchio N. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention. Dermatologic Therapy 2010; 23:458-76; PMID:20868401; http://dx.doi.org/10.1111/j.1529-8019.2010.01350.x
   PubMed Web of Science ®Google Scholar
• Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines: immune responses. Vaccine 2012; 30(Suppl 5):F83-7; PMID:23199968; http://dx.doi.org/10.1016/j.vaccine.2012.04.106
   PubMed Web of Science ®Google Scholar
• Frazer IH. Development and implementation of papillomavirus prophylactic vaccines. J Immunol 2014; 192:4007-11; PMID:24748633; http://dx.doi.org/10.4049/jimmunol.1490012
   PubMed Web of Science ®Google Scholar
• Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341:c33493; http://dx.doi.org/10.1136/bmj.c5128
   Google Scholar
• Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. New Engl J Med 2011; 364:401-11; PMID:21288094; http://dx.doi.org/10.1056/NEJMoa0909537
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED, Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New Engl J Med 2015; 372:711-23; PMID:25693011; http://dx.doi.org/10.1056/NEJMoa1405044
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Inf Dis 2007; 13:28-41; http://dx.doi.org/10.3201/eid1301.060438
   PubMed Web of Science ®Google Scholar
• Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008; 115:947-56; PMID:18503574; http://dx.doi.org/10.1111/j.1471-0528.2008.01743.x
   PubMed Web of Science ®Google Scholar
• Chesson HW, Ekueme DU, Saraiya M, Dunne EF, Markowitz LE. Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States. Vaccine 2013; 31:3899-905; PMID:23820080; http://dx.doi.org/10.1016/j.vaccine.2013.06.050
   PubMed Web of Science ®Google Scholar
• Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012; 104:1712-23; PMID:23104323; http://dx.doi.org/10.1093/jnci/djs395
   PubMed Web of Science ®Google Scholar
• Korostil I, Ali H, Guy R, Donovan B, Law MG, Regan DG. Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males. Sex Transm Dis 2013; 40:833-5; PMID:24113401; http://dx.doi.org/10.1097/OLQ.0000000000000030
   PubMed Web of Science ®Google Scholar
• Brisson M, Van de Velde N, Boily M-C. Different population-level vaccination effectiveness for HPV types 16, 18, 6, and 11. Sex Transm Infect 2011; 87:41-3; PMID:20924049; http://dx.doi.org/10.1136/sti.2010.044412
   PubMed Web of Science ®Google Scholar
• Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. N Z Med J 2011; 124:51-8; PMID:21952330
   PubMedGoogle Scholar
• Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-10. Am J Public Health 2012; 102:833-5
   PubMed Web of Science ®Google Scholar
• Kliewer E, Mahmud SM, Demers AA, et al. Quadrivalent HPV vaccination and the incidence of anogenital warts in Manitoba, Canada. 28th International Papillomavirus Conference; San Juan, Puerto Rico; Nov 30–Dec 6, 2012. Abstract E07-663
   Google Scholar
• Leval A, Herweijer E, Arnheim-Dahlstrom L, Walum H, Frans E, Sparén P, Simard JF. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012; 2016:860-6; http://dx.doi.org/10.1093/infdis/jis405
   Web of Science ®Google Scholar
• Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013; 346:f2032; PMID:23599298; http://dx.doi.org/10.1136/bmj.f2032
   PubMed Web of Science ®Google Scholar
• Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013; 40:130-5; PMID:23324976
   PubMed Web of Science ®Google Scholar
• Howell-Jones R, Soldan K, Wetten S, Mesher D, Williams T, Gill ON, Hughes G. Declining genital warts in young women in England associated with HPV 16/18 vaccination: an ecological study. J Infect Dis 2013; 208:1397-403; PMID:24092908; http://dx.doi.org/10.1093/infdis/jit361
   PubMed Web of Science ®Google Scholar
• Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health 2013; 103:1428-35
   PubMed Web of Science ®Google Scholar
• Mikolajczyck RT, Kraut AA, Horn J, Schulze-Rath R, Garbe E. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany – an ecologic study. Sex Transm Dis 2013; 40:28-31; PMID:23250300; http://dx.doi.org/10.1097/OLQ.0b013e3182756efd
   PubMed Web of Science ®Google Scholar
• Nsouli-Maktabi H, Ludwig SL, Yerubundi UD, Gaydos JC. Incidence of genital warts among US service members before and after the introduction of the quadrivalent human papillomavirus vaccine. MSMR 2013; 20:17-20; PMID:23461306
   PubMedGoogle Scholar
• Sando N, Kofoed K, Zachariae C, Fouchard J. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women – an ecological study. Acta Derm Venereol 2014; 94:288-92; PMID:24150529; http://dx.doi.org/10.2340/00015555-1721
   PubMed Web of Science ®Google Scholar
• Drolet M, Bénard E, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2013; 15:565-80; http://dx.doi.org/10.1016/S1473-3099(14)71073-4
   Web of Science ®Google Scholar
• Schaffer A, Brotherton J, Booy R. Do human papillomavirus vaccines have any role in newborns and the prevention of recurrent respiratory papillomatosis in children? J Paediatr child Health 2007; 43:579-80; PMID:17688640; http://dx.doi.org/10.1111/j.1440-1754.2007.01205.x
   PubMed Web of Science ®Google Scholar
• Shah KV. A case for immunization of human papillomavirus (HPV) 6/11-infected pregnant women with the quadrivalent HPV vaccine to prevent juvenile-onset laryngeal papilloma. J Infect Dis 2014; 209:1307-9; PMID:24265442; http://dx.doi.org/10.1093/infdis/jit611
   PubMed Web of Science ®Google Scholar
• Maloney EM, Unger ER, Tucker RA, Swan D, Karem K, Todd NW, Reeves WC. Longitudinal measures of human papillomavirus 6 and 11 viral loads and antibody response in children with recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2006; 132:711-5; PMID:16847177; http://dx.doi.org/10.1001/archotol.132.7.711
   PubMedGoogle Scholar
• Matys K, Mallary S, Bautista O, Vuocolo S, Manalastas R, Pitisuttithum P, Saah A. Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine. Clin Vaccine Immunol 2012; 19:881-5; PMID:22518014; http://dx.doi.org/10.1128/CVI.00002-12
   PubMed Web of Science ®Google Scholar
• Chirilă M, Bolboacă SD. Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2014 May; 271(5):1135-42; PMID:24121781; http://dx.doi.org/10.1007/s00405-013-2755-y
   PubMed Web of Science ®Google Scholar
• Young DL, Moore MM, Halstead LA. The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma. J Voice 2015 Mar; 29(2):223-9
   PubMed Web of Science ®Google Scholar